PIA
RNAC icon

Piedmont Investment Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Piedmont Investment Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10
Closed -$4K – 2023
2018
Q2 		$4K Buy
+10
New +$3.55K ﹤0.01% 2261

Other funds holding RNAC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Piedmont Investment Advisors's RNAC Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Cartesian Therapeutics (RNAC) in Q3 2018, closing a stake of 10 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in RNAC in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 65 funds tracked by Wall St. Rank hold RNAC as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Cartesian Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 10 Cartesian Therapeutics shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in Cartesian Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Cartesian Therapeutics position peaked at $4K in Q2 2018.
  • 65 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.